GSK plc 6-K, filed Jul 22, 2022
GSK plc (GSK)
6-K
2022-07-22
For: 2022-07-22
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on July 22, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 22 July 2022, London UK
Board and Committee changes
GSK plc (LSE/NYSE: GSK) has today announced the following changes
to its Board and Committees, which took effect immediately
following the demerger of the Consumer Healthcare business on
Monday 18 July 2022 (the Demerger):
|
●
|
Charles Bancroft has
succeeded Vindi Banga as Senior Independent Non-Executive Director.
Mr Bancroft has also been appointed a member of the Remuneration
Committee.
|
|
●
|
Urs Rohner has
been appointed a member of the Audit & Risk
Committee.
|
|
●
|
Dr Anne Beal has
been appointed a member of the Remuneration and Nominations &
Corporate Governance committees.
|
|
●
|
Dr Vishal Sikka who
joined the Board on 18 July 2022 has been appointed a member of the
Corporate Responsibility Committee. In addition, Dr Sikka will
attend Audit & Risk Committee meetings to support the
Committee's oversight of GSK's Digital and Technology
programme.
|
The Board has determined that given the refreshment of the Board
following the Demerger and the Company's renewed focus the whole
Board will engage with the workforce to gather employees'
perspectives rather than designating a specific Non-Executive
Director for this purpose. A programme of events is in place to
facilitate engagement with employees to gather and understand
directly their views.
As previously announced:
|
●
|
Vindi Banga and Dame
Vivienne Cox stepped down
from the GSK Board upon their appointments to the Haleon plc Board
effective on Demerger.
|
|
●
|
Lynn Elsenhans retired
from the Board effective from the Demerger.
|
These changes continue the transition of the Board as an
independent biopharma company post separation. GSK expects to
announce further Non-Executive Director appointments
shortly.
Board and Committee Membership with effect from 18 July
2022:
|
Board Membership
|
|
|
Sir Jonathan Symonds
Emma Walmsley
Iain Mackay
Dr Hal Barron*
Charles Bancroft
Dr Anne Beal
Dr Hal Dietz
Dr Laurie Glimcher
Dr Jesse Goodman
Urs Rohner
Dr Vishal Sikka
|
Non-Executive Chair
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
|
*Dr Barron will transition to a Non-Independent Non-Executive
Director with effect from 1 August 2022.
|
Board Committee
|
Committee Chair
|
Members
|
|
Audit & Risk Committee
|
Charles Bancroft*
|
Dr Anne Beal
Dr Laurie Glimcher
Urs Rohner
|
|
Remuneration Committee
|
Urs Rohner
|
Charles Bancroft
Dr Anne Beal
|
|
Nominations & Corporate Governance Committee
|
Sir Jonathan Symonds
|
Charles Bancroft
Dr Anne Beal
Urs Rohner
|
|
Corporate Responsibility Committee
|
Dr Anne Beal
|
Dr Jesse Goodman
Dr Vishal Sikka
|
|
Science Committee
|
Dr Jesse Goodman**
|
Dr Hal Dietz**
Dr Laurie Glimcher**
Dr Hal Barron (wef 1 August 2022)
|
|
Chairs' Committee
|
Sir Jonathan Symonds
|
Senior Independent Non-Executive Director
Chairs of the Board's Committees
|
* Audit committee financial expert
** Scientific and Medical Expert
Victoria Whyte
Company Secretary
22 July 2022
Notes
|
A. The following information is
available for reference on www.GSK.com:
|
||
|
1.
|
Biographies of each Board member
|
Board of directors and leadership team | GSK
|
|
2.
|
Terms of reference of each Board Committee
|
Committees | GSK
|
|
3.
|
Current Non-Executive Director Fees
|
Non-Executive Director Fees
|
|
B.
|
Mr Bancroft's annual fee increased
by £50,000 per annum when he became GSK's Senior Independent
Non-Executive Director.
|
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Cautionary
statement regarding forward-looking statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
22, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|